Citi raised the firm’s price target on Arcus Biosciences (RCUS) to $45 from $44 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCUS:
- Arcus Biosciences: Casdatifan’s Differentiated HIF-2α Profile Versus Belzutifan Supports High-Risk Buy Rating
- Arcus Biosciences price target raised to $49 from $36 at Leerink
- Arcus Biosciences Highlights Casdatifan Momentum in Call
- Arcus Biosciences reports Q4 EPS (89c), consensus ($1.08)
- Arcus Biosciences files automatic mixed securities shelf